Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21645-21654

  Nakata, Wataru ^a   Uemura, Motohide ^a   Sato, Mototaka ^a   Fujita, Kazutoshi ^a   Jingushi, Kentaro ^b   Ueda, Yuko ^b   Kitae, Kaori ^b   Tsujikawa, Kazutake ^b   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Clear cell carcinoma; MicroRNA; Prognosis; Recurrence; Renal cell carcinoma

Indexed keywords

MICRORNA; MICRORNA 27A 3P; UNCLASSIFIED DRUG; MIRN27 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA CELL LINE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FROZEN SECTION; FUNCTIONAL ASSESSMENT; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RNA ANALYSIS; SURVIVAL RATE; UPREGULATION; VALIDATION STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENETICS; KIDNEY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84940750059     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4064     Document Type: Article

References (28)

1. Murai M, Oya M. Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol. 2004; 14:229-233.
2. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. Group EAoUG: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010; 58:398-406.
3. Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N, Martignoni G, Martorana G, Minervini A, Mirone V, Montorsi F, Schiavina R, Simeone C, Serni S, Simonato A, Siracusano S, Volpe A, Carmignani G. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?. Eur Urol. 2010; 58:588-595.
4. Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 2010; 10:658-664.
5. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331:1559-1564.
6. Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Rehak P, Pummer K, Zigeuner R. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol. 2011; 186:1773-1777.
7. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z, Bjarnason G, Sugar L, Attalah MI, Yousef GM. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn. 2012; 14:385-392.
8. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008; 9:102-114.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857-866.
10. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6:259-269.
11. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, Wu JJ, Ruel NH, Wilczynski SP, Gao H, Covarrubias M, Figlin RA, Weiss LM, Wu H. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One. 2012; 7:e35661.
12. Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ, van Poppel H. Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One. 2012; 7:e38298.
13. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, Kren L, Michalek J, Vyzula R. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res. 2010; 29:90.
14. Wotschofsky Z, Liep J, Meyer HA, Jung M, Wagner I, Disch AC, Schaser KD, Melcher I, Kilic E, Busch J, Weikert S, Miller K, Erbersdobler A, Mollenkopf HJ, Jung K. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci. 2012; 8:1363-1374.
15. Zhao A, Li G, Péoc'h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013; 94:115-120.
16. Shi D, Li P, Ma L, Zhong D, Chu H, Yan F, Lv Q, Qin C, Wang W, Wang M, Tong N, Zhang Z, Yin C. A genetic variant in pre-miR-2a is associated with a reduced renal cell cancer risk in a Chinese population. PLoS One. 2012; 7:e46566.
17. Misra MK, Pandey SK, Kapoor R, Sharma RK, Agrawal S. Genetic variants of MicroRNA-related genes in susceptibility and prognosis of end-stage renal disease and renal allograft outcome among north Indians. Pharmacogenet Genomics. 2014.
18. Jingushi K, Ueda Y, Kitae K, Hase H, Egawa H, Ohshio I, Kawakami R, Kashiwagi Y, Tsukada Y, Kobayashi T, Nakata W, Fujita K, Uemura M, Nonomura N, Tsujikawa K. miRNA-629 Targets TRIM33 to Promote TGF-beta/Smad Signaling and Metastatic Phenotypes in ccRCC. Mol Cancer Res. 2014.
19. Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlbäck B. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer. 2014; 50:1758-1765.
20. Heinzelmann J, Unrein A, Wickmann U, Baumgart S, Stapf M, Szendroi A, Grimm MO, Gajda MR, Wunderlich H, Junker K. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases. Ann Surg Oncol. 2014; 21:1046-1054.
21. Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG, Cairns P. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther. 2014; 15:329-341.
22. Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner K. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014; 5:1174-1184.
23. Huang D, Wang H, Liu R, Li H, Ge S, Bai M, Deng T, Yao G, Ba Y. miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. J Cell Biochem. 2014; 115:549-556.
24. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010; 10:389-402.
25. Zhou L, Yin B, Liu Y, Hong Y, Zhang C, Fan J. Mechanism and function of decreased FOXO1 in renal cell carcinoma. J Surg Oncol. 2012; 105:841-847.
26. Acunzo M, Romano G, Palmieri D, Laganá A, Garofalo M, Balatti V, Drusco A, Chiariello M, Nana-Sinkam P, Croce CM. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci U S A. 2013; 110:8573-8578.
27. Pan W, Wang H, Jianwei R, Ye Z. MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells. Cell Physiol Biochem. 2014; 33:402-412.
28. Camps C, Saini HK, Mole DR, Choudhry H, Reczko M, Guerra-Assunção JA, Tian YM, Buffa FM, Harris AL, Hatzigeorgiou AG, Enright AJ, Ragoussis J. Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Mol Cancer. 2014; 13:28.